Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Woodcock

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
FDA Consumer|October 16, 1999
When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar NordenbergJ Woodcock
Clinical Pharmacology and Therapeutics|April 22, 2010
Precompetitive research: a new prescription for drug development?J Woodcock
Science (New York, N.Y.)|March 9, 1979
The humanities and scienceJ Woodcock
The Journal of Medical Humanities|October 1, 1992
Does Williams' do the right thing? A disagreement between female and male medical students over "The use of force."J Woodcock
Clinical Pharmacology and Therapeutics|April 22, 2014
Drug development in serious diseases: the new "breakthrough therapy" designationJ Woodcock
Clinical Pharmacology and Therapeutics|September 14, 2007
Molecular medicine: how, what, and when?J Woodcock
Clinical Pharmacology and Therapeutics|July 21, 2012
The future of orphan drug developmentJ Woodcock
Clinical Pharmacology and Therapeutics|February 21, 2012
Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs?J Woodcock
Addiction (Abingdon, England)|October 1, 1995
The 1994 annual lecture of the Society for the Study of Addiction. Commissions (Royal and other) on drug misuse: who needs them?J Woodcock
Clinical Pharmacology and Therapeutics|June 19, 2009
Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug developmentJ Woodcock
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
FDA Consumer|October 16, 1999
When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar NordenbergJ Woodcock
Clinical Pharmacology and Therapeutics|April 22, 2010
Precompetitive research: a new prescription for drug development?J Woodcock
Science (New York, N.Y.)|March 9, 1979
The humanities and scienceJ Woodcock
The Journal of Medical Humanities|October 1, 1992
Does Williams' do the right thing? A disagreement between female and male medical students over "The use of force."J Woodcock
Clinical Pharmacology and Therapeutics|April 22, 2014
Drug development in serious diseases: the new "breakthrough therapy" designationJ Woodcock
Clinical Pharmacology and Therapeutics|September 14, 2007
Molecular medicine: how, what, and when?J Woodcock
Clinical Pharmacology and Therapeutics|July 21, 2012
The future of orphan drug developmentJ Woodcock
Clinical Pharmacology and Therapeutics|February 21, 2012
Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs?J Woodcock
Addiction (Abingdon, England)|October 1, 1995
The 1994 annual lecture of the Society for the Study of Addiction. Commissions (Royal and other) on drug misuse: who needs them?J Woodcock
Clinical Pharmacology and Therapeutics|June 19, 2009
Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug developmentJ Woodcock
Pageof 18